David M. Eddy

Last updated
David M. Eddy
Academic background
Alma mater Stanford University, BA
University of Virginia, MD
Stanford University, PhD

David M. Eddy is an American physician, mathematician, and healthcare analyst who has done seminal work in mathematical modeling of diseases, clinical practice guidelines, and evidence-based medicine. [1] [2] [3] Four highlights of his career have been summarized by the Institute of Medicine of the National Academy of Sciences: "more than 25 years ago, Eddy wrote the seminal paper on the role of guidelines in medical decision-making, the first Markov model applied to clinical problems, and the original criteria for coverage decisions; he was the first to use and publish the term 'evidence-based'." [4]

Contents

Education

Eddy attended Phillips Exeter Academy, [5] then received a BA in history from Stanford University, MD from the University of Virginia in 1968, and PhD in Engineering-Economic Systems from Stanford in 1978. [4] [6]

Career

Eddy was Chief of the Bioengineering Branch of the US Army Medical Research and Development Command from 1971 to 1973. After obtaining his PhD, he was an assistant professor (1978) and then professor (1980) of Engineering Economic Systems at Stanford. In 1981, he went to Duke University where he was Professor of Health Policy and Management (1981–1986) and then J. Alexander McMahon Professor of Health Policy and Management (1986–1991). Eddy directed Duke's Center for Health Policy Research and Education from 1981 to 1986. [6] [7] In 1987, he resigned the directorship to focus on research and policy. Other positions include Chief Scientist for Blue Cross Blue Shield's Technology and Coverage Program and Medical Advisory Panel from 1984 to 2005, [3] [7] [8] Director of the World Health Organization's Collaborating Center for Research in Cancer Policy from 1984 to 1996, [9] [10] Senior Advisor to Kaiser Permanente from 1991 to 2006, [3] [11] and Special White House Employee on Hillary Clinton's healthcare task force in 1993. Boards include Consumer Union (1982-1987), Board on Mathematic Sciences and their Applications/National Academy of Sciences, and the National Committee for Quality Assurance (NCQA) (1992–1998). [7] [12] In 2006, with Leonard Schlessinger, Eddy founded Archimedes Inc., a healthcare modeling company funded by Kaiser Permanente. [1] Eddy was Chief Medical Officer of Archimedes until he retired in 2013. Eddy continued to teach and consult after he retired, joining the University of South Florida Institute for Advanced Discovery & Innovation in 2014, where he is a member and courtesy professor. [13]

Research and policy work

Eddy published five books and many papers, including a series of 27 essays in JAMA , the Journal of the American Medical Association. [14] [15] Eddy's work spanned several areas.

Mathematical models in clinical medicine

Eddy was the first to introduce Markov models to clinical medicine. His first model, published in 1976, was designed to analyze screening for cancer. [16] It was used by the Blue Cross Blue Shield Association in 1978 to develop the first set of criteria for the insurance coverage of cancer screening tests. [17] It was then generalized to analyze the progression, monitoring and repair of any probabilistic deteriorating system, and won the 1980 Frederick W. Lanchester Prize for the most important contribution to the field of operations research and management science. [17] [18] The model was used by the American Cancer Society and other organizations to design national and international-level cancer screening policies. [19] This was the first healthcare model to be independently validated against empirical data. [20] In 1987, Eddy developed the CAN*TROL model used by the World Health Organization and National Cancer Institute to help set cancer control priorities both within the United States and Internationally. [21] As a volunteer for WHO, he helped several countries develop cancer control priorities, in particular India, Sri Lanka, and Chile. In 1991, with support from Kaiser Permanente, Eddy began work on a large-scale simulation model of physiology, populations, and healthcare systems, called Archimedes. [3] [22] In 2006, Kaiser Permanente spun out the Archimedes model as a separate corporation. [14] In 2008 the Robert Wood Johnson Foundation provided a $15.5 million grant to make the model readily accessible over the World Wide Web. [23] In 2013 Archimedes, Inc was sold to Evidera. [24]

Clinical practice guidelines

In 1980, Eddy launched the modern guidelines movement in healthcare when he conducted a study for the American Cancer Society to develop recommendations for screening for cancer. [19] This was the first national level policy designed using formal methods instead of expert opinion. It was also controversial for the fact that it eliminated some commonly used tests and recommended for the first time that many tests, such as Pap smears and colon cancer tests, should done at non-annual frequencies. [25] In 1982, Eddy published a seminal paper in the New England Journal of Medicine that described the role clinical policies and guidelines play in medical decision-making, noted their importance in determining the quality of care, and advocated explicit analysis of evidence and estimation of outcomes. [26] The paper prompted the Council of Medical Specialty Societies to hold a national conference on guidelines in 1987, and ask Eddy to conduct a series of workshops to teach specialty societies how to design guidelines using explicit, evidence-based methods. [27] The manual for those workshops was used in the late 1980s by specialty societies and the Institute of Medicine/National Academy of Sciences, [27] [28] and was published in 1992 by the American College of Physicians. [29] Eddy published a series of 27 articles in JAMA from 1991 to 1994 that laid out the rationale and methods for guidelines, and introduced what have subsequently become standard practices in evidence-based guidelines such as distinguishing between standards, guidelines, and options; formulating the decision problem; constructing evidence tables; preparing balance sheets, and being explicit about the quality of the evidence. [30] From 1991 to 2000, Eddy helped Kaiser Permanente set up an evidence-based guidelines program. [11] In 2011 Eddy and colleagues introduced the concept of "individualized guidelines," [31] which involves tailoring treatment recommendations to each individual patient based on that patient's risk factors, taking into account quantitative information about the patient's probabilities of important outcomes, and the effects on those probabilities of different treatments, one-by-one, and in various combinations.

Technology assessment and coverage policies

In 1984 the Blue Cross Blue Shield Association asked Eddy to help them create a formal process and evidence-based criteria for designing coverage policies. From 1984 to 2005 he served as advisor to the association's technology evaluation center, which assesses medical technologies, and chief scientist to the association's medical advisory panel, which recommends coverage policies to BCBS plans nationwide. [7] [32] This work introduced the concept of focusing on health outcomes instead of intermediate outcomes or biomarkers, and set a precedent that before a new test or treatment should be covered there must be good evidence that it is effective in improving health outcomes. The coverage criteria developed under Eddy's guidance were tested and vindicated during the national controversy over high dose chemotherapy and bone marrow transplant for late stage breast cancer. [32] [33] In addition to conducting many assessments, Eddy led the development of new Bayesian methods for synthesizing evidence, called the confidence profile method. [34] This work won the 1991 FHP prize from the International Society of Health Technology Assessment for the most important publication of the year. [35]

Cost-effectiveness analysis

Eddy has been called "the leading expert on cost-effectiveness research and its relationship to public health policy and medical practices." [36] In a series of articles in JAMA, Eddy wrote seminal articles about the importance of taking financial costs into account when designing guidelines and medical policies, and developed theories and methods for setting priorities and rationing healthcare resources. [37] [38] [39] [40] [41] For more than 30 years he has worked with a wide range of national and international-level organizations to apply cost-effectiveness analysis to clinical problems. [19] [42]

Performance measurement

Starting in 1993, Eddy served on NCQA's Committee on Performance Measurement, which designs measures for evaluating the quality of care delivered by health plans and providers. As chair of the methodology subcommittee, he introduced the use of formal, evidence-based methods. [43] In 2011, he published a new approach to measuring performance that spans across multiple diseases and treatments and is based on outcomes, called the Global Outcomes Score. [44]

Evidence-based medicine

In the 1980 ACS Guidelines for Cancer Screening, Eddy laid out the principles for what was to become the evidence-based policies and guidelines movement. [19] "First, there must be good evidence that each test or procedure recommended is medically effective in reducing morbidity or mortality; second, the medical benefits must outweigh the risks; third, the cost of each test or procedure must be reasonable compared to its expected benefits; and finally, the recommended actions must be practical and feasible." [19] Throughout the 1980s he wrote papers that exposed the lack of evidence for many clinical practices. [45] [46] [47] [48] [49] He first began to use the term "evidence-based" in 1988 in his workshops to teach specialty societies how to use formal methods to design guidelines. Eddy was also the first to publish the term "evidence-based." [50] In his formulation, an evidence-based policy "explicitly describes the available evidence that pertains to a guideline and ties the guideline to evidence... [It] consciously anchors a guideline, not to current practices or the beliefs of experts, but to experimental evidence...The hallmark of this approach is that it makes a commitment to evidence – the policy must be consistent with and supported by evidence...The pertinent evidence must be identified, described, and analyzed. The policymakers must determine whether the guideline is justified by the evidence. A rationale must be written." [50] Eddy applied these principles throughout his work to help organizations design coverage policies, guidelines, and performance measures. Although the bulk of his work was in cancer, cardiovascular disease, and diabetes, he also analyzed problems in such disparate fields as radiology, [51] osteoporosis, [52] ophthalmology, and youth suicides. [53] As the "evidence-based" movement began to spread through medicine, additional terms such as "evidence-based medicine" were introduced in the context of medical education and individual physician decision-making. [54] [55] In 2005, Eddy offered a unifying definition: "Evidence-based medicine is a set of principles and methods intended to ensure that to the greatest extent possible, medical decisions, guidelines, and other types of policies are based on and consistent with good evidence of effectiveness and benefit." [56] [57]

Outcomes-based medicine

Throughout his career Eddy has stressed the importance of using quantitative information about the probabilities and magnitudes of health outcomes when making medical decisions or setting medical policies. [26] [58] Eddy began using the term "outcome-based" in his workshops for specialty societies, and first published the term in 1990. [27] [50] He defined the outcomes-based approach as "not only anchoring the guideline to available evidence, but explicitly estimating the outcomes of alternative practices… the guideline must be accompanied not only by a description of the supporting evidence, but also by a description of the important outcomes, the magnitudes of those outcomes, and the method used to derive the estimates." [50]

Selected awards and honors

Related Research Articles

Evidence-based medicine (EBM) is "the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients." The aim of EBM is to integrate the experience of the clinician, the values of the patient, and the best available scientific information to guide decision-making about clinical management. The term was originally used to describe an approach to teaching the practice of medicine and improving decisions by individual physicians about individual patients.

<span class="mw-page-title-main">National Institute for Health and Care Excellence</span> Non-departmental public body of the Department of Health in the United Kingdom

The National Institute for Health and Care Excellence (NICE) is an executive non-departmental public body, in England, of the Department of Health and Social Care, that publishes guidelines in four areas:

<span class="mw-page-title-main">Physical examination</span> Process by which a medical professional investigates the body of a patient for signs of disease

In a physical examination, medical examination, or clinical examination, a medical practitioner examines a patient for any possible medical signs or symptoms of a medical condition. It generally consists of a series of questions about the patient's medical history followed by an examination based on the reported symptoms. Together, the medical history and the physical examination help to determine a diagnosis and devise the treatment plan. These data then become part of the medical record.

<span class="mw-page-title-main">Medical guideline</span> Document with the aim of guiding decisions and criteria in healthcare

A medical guideline is a document with the aim of guiding decisions and criteria regarding diagnosis, management, and treatment in specific areas of healthcare. Such documents have been in use for thousands of years during the entire history of medicine. However, in contrast to previous approaches, which were often based on tradition or authority, modern medical guidelines are based on an examination of current evidence within the paradigm of evidence-based medicine. They usually include summarized consensus statements on best practice in healthcare. A healthcare provider is obliged to know the medical guidelines of their profession, and has to decide whether to follow the recommendations of a guideline for an individual treatment.

<span class="mw-page-title-main">Gordon Guyatt</span> Canadian physician

Gordon Henry Guyatt is a Canadian physician who is Distinguished University Professor in the Departments of Health Research Methods, Evidence and Impact and Medicine at McMaster University in Hamilton, Ontario. He is known for his leadership in evidence-based medicine, a term that first appeared in a single-author paper he published in 1991. Subsequently, a 1992 JAMA article that Guyatt led proved instrumental in bringing the concept of evidence-based medicine to the world's attention.[2] In 2007, The BMJ launched an international election for the most important contributions to healthcare. Evidence-based medicine came 7th, ahead of the computer and medical imaging. [3][4] Guyatt's concerns with the role of the medical system, social justice, and medical reform remain central issues that he promoted in tandem with his medical work. On October 9, 2015, he was named to the Canadian Medical Hall of Fame.

A hierarchy of evidence, comprising levels of evidence (LOEs), that is, evidence levels (ELs), is a heuristic used to rank the relative strength of results obtained from experimental research, especially medical research. There is broad agreement on the relative strength of large-scale, epidemiological studies. More than 80 different hierarchies have been proposed for assessing medical evidence. The design of the study and the endpoints measured affect the strength of the evidence. In clinical research, the best evidence for treatment efficacy is mainly from meta-analyses of randomized controlled trials (RCTs). Systematic reviews of completed, high-quality randomized controlled trials – such as those published by the Cochrane Collaboration – rank the same as systematic review of completed high-quality observational studies in regard to the study of side effects. Evidence hierarchies are often applied in evidence-based practices and are integral to evidence-based medicine (EBM).

Patient safety is a discipline that emphasizes safety in health care through the prevention, reduction, reporting and analysis of error and other types of unnecessary harm that often lead to adverse patient events. The frequency and magnitude of avoidable adverse events, often known as patient safety incidents, experienced by patients was not well known until the 1990s, when multiple countries reported significant numbers of patients harmed and killed by medical errors. Recognizing that healthcare errors impact 1 in every 10 patients around the world, the World Health Organization (WHO) calls patient safety an endemic concern. Indeed, patient safety has emerged as a distinct healthcare discipline supported by an immature yet developing scientific framework. There is a significant transdisciplinary body of theoretical and research literature that informs the science of patient safety with mobile health apps being a growing area of research.

<span class="mw-page-title-main">Lung cancer screening</span>

Lung cancer screening refers to cancer screening strategies used to identify early lung cancers before they cause symptoms, at a point where they are more likely to be curable. Lung cancer screening is critically important because of the incidence and prevalence of lung cancer. More than 235,000 new cases of lung cancer are expected in the United States in 2021 with approximately 130,000 deaths expected in 2021. In addition, at the time of diagnosis, 57% of lung cancers are discovered in advanced stages, meaning they are more widespread or aggressive cancers. Because there is a substantially higher probability of long-term survival following treatment of localized (60%) versus advanced stage (6%) lung cancer, lung cancer screening aims to diagnose the disease in the localized stage.

The United States Preventive Services Task Force (USPSTF) is "an independent panel of experts in primary care and prevention that systematically reviews the evidence of effectiveness and develops recommendations for clinical preventive services". The task force, a volunteer panel of primary care clinicians with methodology experience including epidemiology, biostatistics, health services research, decision sciences, and health economics, is funded, staffed, and appointed by the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality.

<span class="mw-page-title-main">Donald Berwick</span> American government official

Donald M. Berwick is a former Administrator of the Centers for Medicare and Medicaid Services (CMS). Prior to his work in the administration, he was President and Chief Executive Officer of the Institute for Healthcare Improvement a not-for-profit organization.

Disease or patient registries are collections of secondary data related to patients with a specific diagnosis, condition, or procedure, and they play an important role in post marketing surveillance of pharmaceuticals. Registries are different from indexes in that they contain more extensive data.

}}

Shared decision-making in medicine (SDM) is a process in which both the patient and physician contribute to the medical decision-making process and agree on treatment decisions. Health care providers explain treatments and alternatives to patients and help them choose the treatment option that best aligns with their preferences as well as their unique cultural and personal beliefs.

Clinical peer review, also known as medical peer review is the process by which health care professionals, including those in nursing and pharmacy, evaluate each other's clinical performance. A discipline-specific process may be referenced accordingly.

The Improvement Science Research Network (ISRN) is a research network for academics and physicians who are conducting studies in the new medical field of improvement science.

<span class="mw-page-title-main">Peter Bach</span> Medical researcher

Peter B. Bach is a physician and writer in New York City. He is the Chief Medical Officer of DELFI Diagnostics and was previously an attending and researcher at Memorial Sloan-Kettering Cancer Center where he was the Director of the Center for Health Policy and Outcomes. His research focuses on healthcare policy, particularly as it relates to Medicare, racial disparities in cancer care quality, and lung cancer. Along with his scientific writings he is a frequent contributor to The New York Times and other newspapers.

Health care quality is a level of value provided by any health care resource, as determined by some measurement. As with quality in other fields, it is an assessment of whether something is good enough and whether it is suitable for its purpose. The goal of health care is to provide medical resources of high quality to all who need them; that is, to ensure good quality of life, cure illnesses when possible, to extend life expectancy, and so on. Researchers use a variety of quality measures to attempt to determine health care quality, including counts of a therapy's reduction or lessening of diseases identified by medical diagnosis, a decrease in the number of risk factors which people have following preventive care, or a survey of health indicators in a population who are accessing certain kinds of care.

Chlamydia research is the systematic study of the organisms in the taxonomic group of bacteria Chlamydiota, the diagnostic procedures to treat infections, the disease chlamydia, infections caused by the organisms, the epidemiology of infection and the development of vaccines. The process of research can include the participation of many researchers who work in collaboration from separate organizations, governmental entities and universities.

ISPOR—The Professional Society for Health Economics and Outcomes Research, better known as ISPOR, is a nonprofit global professional organization in health economics and outcomes research. It was founded in 1995 as an international multidisciplinary professional organization that advances the policy, science, and practice of pharmacoeconomics and outcomes research. The society's mission is to promote health economics and outcomes research to improve decision making for health globally.

<span class="mw-page-title-main">Psychosocial distress</span>

Psychosocial distress refers to the unpleasant emotions or psychological symptoms an individual has when they are overwhelmed, which negatively impacts their quality of life. Psychosocial distress is most commonly used in medical care to refer to the emotional distress experienced by populations of patients and caregivers of patients with complex chronic conditions such as cancer, diabetes, and cardiovascular conditions, which confer heavy symptom burdens that are often overwhelming, due to the disease's association with death. Due to the significant history of psychosocial distress in cancer treatment, and a lack of reliable secondary resources documenting distress in other contexts, psychosocial distress will be mainly discussed in the context of oncology.

References

  1. 1 2 "Medical Guesswork". Bloomberg Businessweek Magazine. Archived from the original on August 9, 2012. Retrieved 7 May 2014.
  2. ↑ "Evidence-Based Medicine: A Unified Approach" (PDF). Health Affairs. Retrieved 7 May 2014.
  3. 1 2 3 4 "Modeling Human Drug Trials – Without the Human". Wired . Vol. 17, no. 12. 2009-11-15. Retrieved 7 May 2014.
  4. 1 2 "The Learning Healthcare System: Workshop Summary". National Academies Press. Retrieved 7 May 2014.
  5. ↑ "Taking the guesswork out of medicine". Phillips Exeter Academy. Retrieved 2018-08-13.
  6. 1 2 "Evidence-Based Guidelines Affecting Policy, Practice and Stakeholders (E-GAPPS)" (PDF). The New York Academy of Medicine. Archived from the original (PDF) on 12 May 2014. Retrieved 7 May 2014.
  7. 1 2 3 4 "Meet the Experts". PBS . Retrieved 7 May 2014.
  8. ↑ "Imagining and Constructing SimCity for Health Care Systems: A Progress Report from the Architect". Stanford. September 2008. Retrieved 7 May 2014.
  9. ↑ "Plotting a new course for cervical cancer screening in developing countries" (PDF). World Health Forum. Retrieved 7 May 2014.
  10. ↑ "Advancing Evidence-Based Health Care: New Tools, New Data, New Opportunities" (PDF). National Health Policy Forum. Retrieved 7 May 2014.
  11. 1 2 Davino-Ramaya C, Krause LK, Robbins CW, Harris JS, Koster M, Chan W, Tom GI (2012). "Transparency Matters: Kaiser Permanente's National Guideline Program Methodological Processes". The Permanente Journal. 16 (1): 55–62. doi:10.7812/tpp/11-134. PMC   3327114 . PMID   22529761.
  12. ↑ "Speaker Biography". Society for Medical Design Making. 2013-10-21. Retrieved 7 May 2014.
  13. ↑ "Overview of the Institute for Advanced Discovery & Innovation".
  14. 1 2 "Healthcare Modeling Part 4: How the Archimedes Model Works and is Validated". X Talks. Archived from the original on 12 May 2014. Retrieved 7 May 2014.
  15. ↑ "About the Authors". Value in Health. 12: S50–S53. 2009. doi: 10.1111/j.1524-4733.2009.00560.x .
  16. ↑ Eddy DM (November 1976). "A Methodology for Evaluating Breast Cancer Screening Programs". Proceedings of the International Conference on Cybernetics and Society.
  17. 1 2 Eddy DM (1980). "Screening for Cancer: Theory, Analysis and Design". Prentice-Hall, Inc.
  18. ↑ "Frederick W. Lanchester Prize". informs. Archived from the original on 31 December 2010. Retrieved 7 May 2014.
  19. 1 2 3 4 5 "Guidelines for the Cancer-Related Checkup. Recommendations and Rationale". 30. Ca-A Cancer Journal for Clinicians. 1980: 193–240.{{cite journal}}: Cite journal requires |journal= (help)
  20. ↑ Eddy DM (1987). "The Frequency of Cervical Cancer Screening. Comparison of a Mathematical Model with Empirical Data". Cancer. 60 (5): 1117–1122. doi:10.1002/1097-0142(19870901)60:5<1117::aid-cncr2820600533>3.0.co;2-h. PMID   3607728. S2CID   30881085.
  21. ↑ Eddy DM (1987). "CAN*TROL: A Computer Model for Designing National Cancer Control Strategies". 74 (3). Bull Cancer: 323–32.{{cite journal}}: Cite journal requires |journal= (help)
  22. ↑ "Archimedes: a new model for simulating health care systems—the mathematical formulation". Journal of Biomedical Informatics. Retrieved 7 May 2014.
  23. ↑ "The Archimedes Healthcare Simulator (ARCHeS)". Robert Wood Johnson Foundation. Archived from the original on 12 May 2014. Retrieved 7 May 2014.
  24. ↑ "Archimedes, A leader in healthcare simulation is acquired by Evidera, a Symphony Technology Group Company". Evidera. Retrieved 7 May 2014.[ permanent dead link ]
  25. ↑ Brody, Jane E. (1980-03-21). "Cancer Society Reports It Finds Some Detection Tests Unneeded; Change in Lung-Test Policy Cancer Society Reports It Finds Some Detection Tests Unneeded Revisions in Detail Clarifying 'Periodic' Checkup". New York Times. Retrieved 7 May 2014.
  26. 1 2 Eddy DM (1982). "Clinical Policies and the Quality of Clinical Practice". New England Journal of Medicine. 307 (6): 343–347. doi:10.1056/nejm198208053070604. PMID   7088099.
  27. 1 2 3 Richard Wilbur, preface to Eddy, DM (1992). A Manual for Assessing Health Practices and Designing Practice Policies: The Explicit Approach. Philadelphia, Pennsylvania: American College of Physicians.{{cite book}}: CS1 maint: multiple names: authors list (link)
  28. ↑ Institute of Medicine (US) Committee to Advise the Public Health Service on Clinical Practice Guidelines; Field, M. J.; Lohr, K. N. (1990). Clinical Practice Guidelines. National Academies. doi:10.17226/1626. ISBN   978-0-309-04346-5. PMC   5310095 . PMID   25144032 . Retrieved 7 May 2014.
  29. ↑ Eddy, David M (1992). "A Manual for Assessing Health Practices and Designing Practice Policies: The Explicit Approach". American College of Physicians.
  30. ↑ Eddy DM (1996). "Clinical Decision Making. From Theory to Practice: A Collection of Essays Published by the American Medical Association". Jones and Bartlett Publishers.{{cite journal}}: Cite journal requires |journal= (help)
  31. ↑ Eddy DM; Adler J; Patterson B; Lucas D; Smith KA; Morris M (2011). "Individualized Guidelines: the Potential for Increasing Quality and Reducing Costs". Ann Intern Med. 154 (9): 627–34. CiteSeerX   10.1.1.671.5281 . doi:10.7326/0003-4819-154-9-201105030-00008. PMID   21536939. S2CID   21006240.
  32. 1 2 False Hope : Bone Marrow Transplantation for Breast Cancer. Oxford University Press. 2007-01-25. ISBN   9780199748242 . Retrieved 7 May 2014.
  33. ↑ Eddy DM (1992). "High-Dose Chemotherapy with Autologous Bone Marrow Transplantation for the Treatment of Metastatic Breast Cancer". Journal of Clinical Oncology. 10 (4): 657–670. doi:10.1200/JCO.1992.10.4.657. PMID   1285731.
  34. ↑ Eddy DM; Hasselblad V; Shachter R (1992). "The Statistical Synthesis of Evidence: Meta-Analysis by the Confidence Profile Method". Academic Press.{{cite journal}}: Cite journal requires |journal= (help)
  35. ↑ "The International Society for Technology Assessment in Health Care Seventh Annual Meeting Helsinki". Vol. 7. Finland International Journal of Technology Assessment in Health Care. 1991. pp. 119–120.
  36. ↑ "The Interface Interview: a Conversation with Dr. David Eddy". Medical Interface. 1992. pp. 17–23.
  37. ↑ Eddy DM (1990). "What Do We Do About Costs?". 264. Journal of the American Medical Association: 1161, 1165, 1169–1170.{{cite journal}}: Cite journal requires |journal= (help)
  38. ↑ Eddy DM (1990). "Connecting Value and Cost: Whom Do We Ask and What Do We Ask Them?". JAMA. 264 (13): 1737–1739. doi:10.1001/jama.1990.03450130109039.
  39. ↑ Eddy DM (1991). "Rationing by Patient Choice". JAMA: The Journal of the American Medical Association. 265 (1): 105–108. doi:10.1001/jama.265.1.105. PMID   1984107.
  40. ↑ Eddy DM (1994). "Health System Reform. Will Controlling Costs Require Rationing Services?". JAMA. Journal of the American Medical Association. 272 (4): 272, 324–328. doi:10.1001/jama.272.4.324. PMID   7888005.
  41. ↑ Eddy DM (1994). "Rationing Resources While Improving Quality: How to Get More for Less". JAMA. 272 (10): 817. doi:10.1001/jama.1994.03520100085041.
  42. ↑ Eddy DM; Shah R (2012). "A Simulation Shows Limited Savings From Meeting Quality Targets Under The Medicare Shared Savings Program Health Affairs". Vol. 31, no. 11. pp. 2554–62.
  43. ↑ Eddy DM (July–August 1998). "Performance Measurement: Problems and Solutions". Health Affairs.
  44. ↑ Eddy DM; Adler J; Morris M (2012). "The 'Global Outcomes Score': A Quality Measure, Based on Health Outcomes, That Compares Current Care to a Target Level of Care Health Affairs". Vol. 31, no. 11. pp. 2441–2450.
  45. ↑ Eddy DM (1982). "Probabilistic Reasoning in Clinical Medicine: Problems and Opportunities". Cambridge University Press.
  46. ↑ Eddy DM; Sanders L; Eddy JF. "The Value of Screening for Glaucoma with Tonometry". Vol. 28. Survey of Ophthalmology 1983. pp. 194–205.
  47. ↑ Eddy DM (Winter 1983). "Flying Without Instruments: Analyzing Medical Policies by Consensus and Expert Opinion". The John A Hartford Foundation Bulletin.
  48. ↑ Eddy DM. "Variations in Physician Practice. The Role of Uncertainty". Vol. 3. Health Affairs 1984. pp. 74–89.
  49. ↑ Eddy DM (Spring 1988). "The Quality of Medical Evidence: Implications for Quality of Care". Vol. 7, no. 1. Health Affairs. pp. 19–32.
  50. 1 2 3 4 Eddy DM (1990). "Practice Policies— Where Do They Come from?". 263. Journal of the American Medical Association: 1265, 1269, 1272, 1275.{{cite journal}}: Cite journal requires |journal= (help)
  51. ↑ Eddy DM (1992). "Applying Cost-Effectiveness Analysis: The Inside Story". Journal of the American Medical Association. 268 (18): 2575–2582. doi:10.1001/jama.1992.03490180107037.
  52. ↑ Melton LJ, Eddy DM, Johnston CC Jr (1990). "Screening for osteoporosis". Ann Intern Med. 112 (7): 516–28. doi:10.7326/0003-4819-112-7-516. PMID   2180356.
  53. ↑ Rosenberg, Mark L.; Baer, Katie (1988-12-31). "Report of the Secretary's Task Force on Youth Suicide. Volume 4: Strategies for the Prevention of Youth Suicide". ERIC. Retrieved 7 May 2014.{{cite journal}}: Cite journal requires |journal= (help)
  54. ↑ Guyatt Gordon (1992). "Evidence-based Medicine: a New Approach to Teaching the Practice of Medicine". Journal of the American Medical Association. 268 (17): 2420–5. doi:10.1001/jama.1992.03490170092032. PMID   1404801.
  55. ↑ Sackett, DL (1996). "Evidence-based Medicine: What It Is and What It Isn't". British Medical Journal. 312 (7023): 71–72. doi:10.1136/bmj.312.7023.71. PMC   2349778 . PMID   8555924.
  56. ↑ Eddy, DM (2005). "Evidence-based Medicine: a Unified Approach". Vol. 24. Health Affairs. pp. 9–17.
  57. ↑ "An Evidence-Based Approach To Communicating Health Care Evidence To Patients". Health Affairs. 2012. doi:10.1377/forefront.20120925.023434.{{cite journal}}: Cite journal requires |journal= (help)
  58. ↑ Eddy DM (1990). "Guidelines – How Should They Be Designed?". 263. Journal of the American Medical Association: 1839–1841.{{cite journal}}: Cite journal requires |journal= (help)
  59. ↑ "Previous Winners". Academy of Managed Care Pharmacy. Retrieved 7 May 2014.
  60. ↑ "National Academy of Inventors".
  61. ↑ "Awardees & Honorary Degrees | Commencement | University of South Florida".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.